Cellix Launches Semi-Automated, High Throughput Cell-Adhesion Assay Platform
Complete the form below to unlock access to ALL audio articles.
Cellix Ltd. has announced that its worldwide launch of its VenaFlux™ Platform. The VenaFlux™, the first semi-automated, high throughput microfluidic cell- based assay system, measures cell adhesion to antibody-coated or endothelial- cell cultured microchannels, producing IC50 curves under shear stress conditions mimicking physiological flow.
The system thereby is designed to offer scientists an important and tool for drug discovery. The VenaFlux™ is simple to use, reduces layers of animal model studies, and delivers specific and reproducible results, the company claims.
Using the VenaFlux™, scientists can obtain quantitative analyses and results for potential drug candidates in therapeutic areas including cardiovascular, respiratory, immunologic, autoimmune and oncologic disease states.
"Understanding how cells behave in human capillaries is an expanding area in global research and development for discovering new patient therapies," said Vivienne Williams, CEO of Cellix Ltd. "Our VenaFlux™ accurately replicates cell behavior in human capillaries, an in vitro modeling system that has previously been difficult to achieve.
Cellix's technology can provides researchers with a single platform for executing dynamic studies to analyze the effects of drugs on cell adhesion, proliferation and transmigration under well-defined shear stress protocols that replicate physiological conditions. "To date, pharmaceutical companies including AstraZeneca and Amgen, as well as research institutions such as the US National Institutes of Health have adopted Cellix's technology to characterize drug effects," commented Ms. Williams.
